The SLICC group has made a significant commitment to building the world’s largest biorepository of DNA, plasma and serum on an extremely well phenotyped inception cohort of SLE patients. DNA is collected at patient enrolment and serum and plasma samples are collected annually. Our cohort consists of 1835 patients and our biobank currently holds 1378 DNA samples and over 9600 serum and plasma samples. At present we have over 500 patients that have been followed for over 10 years, thus creating a valuable resource of both biospecimens and corresponding clinical data on an inception cohort of SLE patients.
Some of the exciting research SLICC investigators have conducted as a result of using the SLICC biobank include: the impact of early disease factors on metabolic syndrome in SLE and vitamin D deficiency and its association with increased risk for cardiovascular disease risk factors. The biobank will serve as a useful resource for studies looking at clinical-serologic correlations, the role of genetics in disease susceptibility and expression.